A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia

CONCLUSIONS: Ipilimumab plus nivolumab demonstrated efficacy in chemotherapy-refractory GTN, an ultra-rare cancer affecting young women. Three out of four patients achieved ongoing objective responses with a reasonable safety profile at 6-11+ months.PMID:37882676 | DOI:10.1158/1078-0432.CCR-23-2293

Source: Clinical Cancer Research - October 26, 2023 Category: Cancer & Oncology Authors: Sandip P Patel Megan Othus Young Kwang Chae Michael J Dennis Sarah Gordon David Mutch Wolfram Samlowski William R Robinson Elad Sharon Christopher Ryan Gabby Lopez Melissa Plets Charles Blanke Razelle Kurzrock Source Type: research